Merck KGaA confirmed that it may divest its generic business. Analysts estimate its value at $4 billion (Euro 3 billion). According to the company, the sale is one strategic option being considered as a means for the business to realize its potential and strengthen its market position. Merck's generics business is considered one of the top four players in the industry. Ranbaxy and other Indian pharma companies looking to increase their presence in the international marketplace are likely candidates to make such an acquisition. Possible European contenders include Barr, Sandoz, Sanofi-Aventis, and Actavis. Private equity firms like Blackstone and Kohlberg Kravis Roberts & Co. (KKR) could be in the running as well. |
|
Back to News
